Phase 2a GATEWAY Trial of PORT-77 in Patients With Erythropoietic Protoporphyria Shows Promise by Madaline Spencer| Published on: Jul 31, 2026

Phase 2a GATEWAY Trial of PORT-77 in Patients With Erythropoietic Protoporphyria Shows Promise by Madaline Spencer| Published on: Jul 31, 2026 Pete Schmidt, MD, MSc, Chief Medical Officer of Portal Therapeutics, discusses data from the phase 2a GATEWAY trial testingPORT-77, an ABCG2 inhibitor, in patients with erythropoietic protoporphyria (EPP). https://checkrare.com/phase-2a-gateway-trial-of-port-77-in-patients-with-erythropoietic-protoporphyria-shows-promise/